No abstract

No abstract

No abstract

Introduction: The implications of race coefficient removal from the eGFR estimation equations on the pool of eligible Black patients with HFrEF and/or CKD for initiation of the Sodium Glucose Co-Transporter-2 inhibitors (SGLT2i) have not been evaluated. Hypothesis: To determine the change in eligibility by eGFR criteria for Black patients with HFrEF (EF< 40%) and CKD for initiation of dapagliflozin with/without race inclusion in computing eGFR. Methods: Retrospective single-center analysis of Black patients with HFrEF (EF<40%) hospitalized with a diagnosis of acute heart failure. Patients on any modality of dialysis were excluded. The serum creatinine value on discharge was used to compute eGFR using both MDRD and CKD-EPI formulae with and without the race coefficient. Eligibility eGFR value for initiation dapagliflozin for HFrEF was set at >25cc/min/1.73m 2 , and the eGFR range of interest for initiation in CKD was set at the 25-75cc/min/1.73m 2 range. Results: A total of 396 Black patients were included in the analysis of which 62% were men. The mean age was 64±15 years and 37% had CKD stage 3-5. The proportion of patients eligible for initiation of dapagliflozin (eGFR>25cc/min/1.73m 2 ) for HFrEF did not change significantly (93% with race vs 91% without race p=0.431 for MDRD and 92% vs 90% p=0.450 for CKD-EPI). On the other hand, the proportions for patients eligible by CKD eGFR range of 25 to 75 cc/min/1.73m 2 significantly increased with eGFR estimated without the race coefficient. This was true for both the MDRD and CKD-EPI equations (see Figure 1). Conclusions: The proportion of eligible patients for SGLT2i therapy (HFrEF and CKD) significantly increased when eGFR was computed without the race coefficient, driven by an increased CKD stage 3 range re-classification. Race coefficient removal in computation of eGFR did not adversely impact eligibility for SGLT2i when used for HFrEF.

No abstract